ReCode Therapeutics
Created in 2015
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
429 14,971Activities
Technologies
Entity types
Location
Menlo Park, CA, USA
Menlo Park
United States of America
Employees
Scale: 11-50
Estimated: 120
Engaged corporates
4
1 4Added in Motherbase
1 year, 7 months ago
deeptech Value proposition
Powering the next wave of genetic medicines through superior delivery
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology
ReCode Therapeutics - Powering the future of genetic medicines through superior delivery
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
https://recodetx.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Amgen Biotechnology, Biotechnology Research | Amgen Biotechnology, Biotechnology Research | Other 29 Jun 2022 | | |
 Credit Suisse Bank | Credit Suisse Bank | Other 2 Nov 2022 | | |
 Bayer Pharmaceutical, Chemistry, Chemical Manufacturing | Bayer Pharmaceutical, Chemistry, Chemical Manufacturing | Other 9 Jan 2023 | | |
 Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 12 Jul 2022 | | |